Summary
The SWIFT PRIME study demonstrated that the Solitaire stent was safe and effective at reducing poststroke disability in patients with acute ischemic stroke. Functional independence (mRS of 0 to 2) at 90 days was achieved in 60.2% of patients in the Solitaire plus IV tPA group vs 35.5% in the IV tPA group (P < .0008).
- acute ischemic stroke
- disability
- endovascular
- reperfusion
- Solitaire
- stent
- SWIFT PRIME
- tPA
- © 2015 SAGE Publications
Tools
Solitaire Stent Reduced Disability in Stroke Patients in the SWIFT PRIME Trial
Permalink:
Table of contents
Cited By...
- No citing articles found.